Xiangxue Pharmaceutical Co., Ltd. Class A

Xiangxue Pharmaceutical Co., Ltd. Class A

SSZSE:300147
5.45
CNY
-0.57
(-9.47%)
-2.15EPS
3.90BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A carries a market capitalization of 3.90B, placing it among publicly traded companies globally. Its enterprise value stands at 5.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.90B
Enterprise Value5.53B

Share Statistics

As of September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A has 661.28M shares outstanding.

Shares Outstanding661.28M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 2.57, and the price-to-book ratio stands at -5.05.

PS Ratio2.57
PB Ratio-5.05
P/TBV Ratio-2.00

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.53B versus a market cap of 3.90B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.65

Financial Position

As of September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A maintains a current ratio of 0.23, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -379.05, indicating conservative leverage, while an interest coverage ratio of -3.12 demonstrates limited ability to service its debt obligations.

Current Ratio0.23
Quick Ratio0.02
Debt / Equity-379.05
Debt / EBITDA-1.72
Interest Coverage-3.12

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -20.63, reflecting losses generated across the asset base. The company generates approximately 568,601.79 in revenue per employee across its workforce of 2,662.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.99 indicates how many times Xiangxue Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-20.63
Revenue Per Employee568,601.79
Employee Count2,662.00
Inventory Turnover3.99

Taxes

CNY

Over the twelve months ended September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A recorded 49.20M in income tax expense. The company reported a pretax loss of -1.37B and -1.45B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax49.20M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A's stock has declined approximately 44.84% over the past 52 weeks. The 50-day moving average sits at 5.58, while the 200-day moving average is 8.19.

52-Week Price Change-44.84%
50-Day Moving Average5.58
200-Day Moving Average8.19

Income Statement

CNY

Over the twelve months ended September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A generated 1.51B in revenue and converted that into -1.45B in net income, yielding earnings per share of -2.15. EBITDA reached -806.28M, while operating income came in at 3.84M.

Revenue1.51B
Gross Profit412.15M
Operating Income3.84M
Pretax Income-1.37B
Net Income-1.45B
EBITDA-806.28M
EBIT-806.28M
Earnings Per Share (EPS)-2.15

Balance Sheet

CNY

As of September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A holds 165.45M in cash and equivalents against 1.39B in total debt, resulting in a net debt position of 641.87M. Total book value stands at -772.90M, with working capital of -5.29B providing operational flexibility.

Cash & Cash Equivalents165.45M
Total Debt1.39B
Net Debt641.87M
Equity (Book Value)-772.90M
Book Value Per Share-1.17
Working Capital-5.29B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-27.06M

Margins

Over the twelve months ended September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A posted a gross margin of 27.23, reflecting its pricing power and cost economics. The operating margin of 0.25 and net profit margin of -95.67 provide insight into operational efficiency.

Gross Margin27.23
Operating Margin0.25
Pretax Margin-90.36
Profit Margin-95.67
EBITDA Margin-53.27

Dividends & Yields

Over the twelve months ended September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.11 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.12, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Xiangxue Pharmaceutical Co., Ltd. Class A shareholders.

Payout Ratio-0.11
Shareholder Yield0.12

Stock Splits

Xiangxue Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 18, 2015 with a 173:209 split ratio.

Last Split Date6/18/2015
Split Ratio173:209

Scores

As of September 30, 2026, Xiangxue Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of -1.48, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.48